Biotech | March 29, 2022
USFDA clears IND application for an intranasal RSV vaccine
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
It has also been granted permission to conduct trials for booster dose
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Goal of providing 12-month internship opportunities for qualified students
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated
